Efficacy and safety of bevacizumab combined with chemotherapy in treatment of EGFR wild type or EGFR-TKI resistant lung adenocarcinoma with brain metastases / 肿瘤

ABSTRACT

Objective: There is no standard chemotherapy regimen for patients with wild type epidermal growth factor receptor (EGFR) and EGFRtyrosine kinase inhibitor (TKI) resistant lung adenocarcinoma with brain metastases. This study aims to observe the efficacy and toxicity of chemotherapy combined with bevacizumab in wild-type EGFR and EGFR-TKI resistant lung adenocarcinoma patients with brain metastases. Methods: A total of 10 lung adenocarcinoma patients with brain metastases between January and December 2015 received bevacizumab and chemotherapy. The response was evaluated by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) every 2 cycles and the toxicity was evaluated by National Cancer Institute-Common Toxicity Criteria version 3.0 (NCI-CTC 3.0) every cycle. Results: Of the eight patients who could be evaluated for response, the overall response rate was 25% (2/8) and the disease control rate was 75% (6/8). And for intracranial lesions, the response rate was 12% (1/8) and the disease control rate was 87% (7/8). The most commonly adverse events induced by bevacizumab were hypertension, proteinuria and bleeding, which were mostly degrees I-II. Conclusion: Bevacizumab combined with chemotherapy is an effective and safe treatment method for EGFR wild type and EGFR-TKI resistant lung adenocarcinoma patients with brain metastases.